SLC5A2 and hydrops fetalis: Beyond the established benefits of SGLT2 inhibitors in HF, there is emerging evidence that this medication class exhibits pleiotropic effects with benefits for patients with other cardiovascular conditions, including valvular heart disease, IHD, arrythmias, and cardiomyopathies, and in cardio-oncology patients [21].